Rockwell Medical Inc. (NASDAQ:RMTI)’s share price dropped 1.7% during trading on Thursday . The company traded as low as $7.03 and last traded at $7.04, with a volume of 243,476 shares. The stock had previously closed at $7.16.

Several equities analysts have recently issued reports on the stock. BTIG Research assumed coverage on shares of Rockwell Medical in a report on Friday, August 19th. They set a “buy” rating and a $12.00 price objective on the stock. Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Friday, May 13th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $11.00.

The firm’s market cap is $359.65 million. The firm has a 50-day moving average of $7.65 and a 200 day moving average of $7.85.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm earned $12.50 million during the quarter, compared to analyst estimates of $13.86 million. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. Analysts expect that Rockwell Medical Inc. will post ($0.36) earnings per share for the current year.

In other news, Director Kenneth L. Holt sold 3,692 shares of Rockwell Medical stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $7.31, for a total value of $26,988.52. Following the completion of the transaction, the director now owns 63,475 shares in the company, valued at approximately $464,002.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.